Four Decades of Progress in Heart-Lung Transplantation: 271 Cases at a Single Institution.
Stefan Elde,Basil M. Baccouche,Danielle M. Mullis,Matthew M. Leipzig,Tobias Deuse,Aravind Krishnan,Moeed Fawad,Reid Dale,Sabrina Walsh,Amanda Padilla-Lopez,Brandon Wesley,Hao He,Shin Yajima,Yuanjia Zhu,Hanjay Wang,Brandon A. Guenthart,Yasuhiro Shudo,Bruce A. Reitz,Y. Joseph Woo
DOI: https://doi.org/10.1016/j.jtcvs.2024.01.042
IF: 6.439
2024-02-07
Journal of Thoracic and Cardiovascular Surgery
Abstract:Objective The objective of this study is to evaluate survival for combined heart-lung transplant (HLTx) recipients across four decades at a single institution. We aim to summarize our contemporary practice based upon more than 271 HLTx over 40 years. Methods Data were collected from a departmental database and the United Network for Organ Sharing (UNOS). Recipients <18y, those undergoing redo HLTx , or triple-organ system transplantation were excluded, leaving 271 patients for analysis. The Pioneering Era was defined by date of transplant between 1981-2000 (N=155), and the Modern Era between 2001-2022 (N=116). Survival analysis was performed using cardinality matching of populations based on donor and recipient age, donor and recipient sex, ischemic time, and sex-matching. Results Between 1981-2022, 271 HLTx were performed at a single institution. Recipients in the Modern Era were older (42 vs 34y, P<0.001) and had shorter waitlist times (78 vs 234d, P<0.001). Allografts from female donors were more common in the Modern Era (59% vs 39%, P=0.002). In the matched survival analysis, 30-day survival (97% vs 84%, P=0.005), 1-year survival (89% vs 77%, P=0.041), and 10-year survival (53% vs 26%, P=0.012) significantly improved in the Modern Era relative to the Pioneering Era, respectively. Conclusions Long-term survival in HLTx is achievable with institutional experience and may continue to improve in the coming decades. Advances in mechanical circulatory support, improved maintenance immunosuppression, and early recognition and management of acute complications such as primary graft dysfunction and acute rejection have dramatically improved the prognosis for HLTx recipients in our contemporary institutional experience.
surgery,cardiac & cardiovascular systems,respiratory system